Once-Weekly Eli Lilly Diabetes Drug Wins FDA Approval
The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.
The once-weekly drug belongs to a family of diabetes treatments called GLP-1 receptor agonists, which includes Novo Nordisk's widely used daily treatment Victoza. They act like GLP-1, a natural hormone, in prodding the body to release insulin when patients eat.
Help employers find you! Check out all the jobs and post your resume.
The once-weekly drug belongs to a family of diabetes treatments called GLP-1 receptor agonists, which includes Novo Nordisk's widely used daily treatment Victoza. They act like GLP-1, a natural hormone, in prodding the body to release insulin when patients eat.
Help employers find you! Check out all the jobs and post your resume.